- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01123655
Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients
Phase 1 Trial of CII APL A12 in Rheumatoid Arthritis Patients
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The study will have 3 treatment arms each with 10 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 3 treatment arms. Each of the 3 treatments will be given for 16 weeks.
In keeping with a sequential dose escalation strategy, the originally proposed randomization scheme will be modified so that subjects will be randomized to receive either the lowest dose (30 mg) or placebo (Block 1), followed by the next dose (50 mg) or placebo (Block 2). We will begin with the lowest dose (30 g/day) and enroll 6 to receive 30 g/day APL A12 and 2 to receive placebo for 16 weeks. Results will be reported to the Data Monitoring Committee (DMC) for a decision to proceed to the next block based on indications of safety. If this dose does not cause adverse events or toxicity or worsens RA, we will proceed to enroll patients to receive 30 ug, or 50 g/day APL A12 or placebo for 16 weeks. A total of 32 subjects will be randomized to obtain 24 subjects who complete the study. Recruitment was difficult. Only 22 patients were randomized. There were not enough 50mcg patients enrolled so 2 treatment groups was analyzed. Arm 1 included 30 and 50 mcg and Arm 2 represents the patients that received placebo.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater, 38104
- Memphis VA Medical Center, Memphis, TN
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Patients must meet the following criteria for participation in the study.
- Male or female; age > 18 years.
- American College of Rheumatology (ACR) 1988 revised criteria for rheumatoid arthritis.
- Onset of disease age 16 or older.
- Onset of disease at least 3 months prior to enrollment.
- RA patients ages 18-85 with RA of 3 month duration which in the opinion of the examining rheumatologist is "clinically stable" and will likely not require adjustment of doses of Disease-modifying antirheumatic drugs (DMARDS), NSAIDS, prednisone, anti-tumor necrosis factor (anti-TNF) alpha therapies for the 16 weeks of the treatment phase of the study.
- Patients must agree to discontinue all "herbal remedies" as described in this protocol.
- Women of childbearing age will be advised to use effective means of contraception for the treatment phase of the trial and for 90 days thereafter. They must have a negative urine pregnancy test at the randomization visit. (Required by the FDA.)
- Men will be advised to use effective means of contraception for the treatment phase of the trial and for 90 days thereafter. (Required by the FDA.)
- Crohn's Disease Activity Index (CDAI) less than or equal to 30 at the baseline visit.
- Patients with a past history of malignant neoplasm will be eligible if they are 1 or greater years with no recurrence of malignant neoplasm.
Exclusion Criteria:
- Inability to render an informed consent in accordance with institutional guidelines.
- Participation in another clinical research study involving the evaluation of another investigational drug within 90 days of entry into this study.
- RA patients on >7.5 mg prednisone a day.
- RA patients with intra-articular corticosteroid injections during the previous 30 days.
- Concurrent serious medical condition which in the opinion of the investigator makes the patient inappropriate for the study. Hepatitis B abd/or C patients with inactive disease (as determined by PI) will be enrolled.
- Positive urine pregnancy test
- Age 85 years or greater.
- Use of "fish oil" within the previous 4 weeks of the baseline visit.
- Therapy consisting of auranofin or cyclophosphamide (all other DMARDs are allowed).
- Previous autologous or heterologous stem cell transplantation.
- Active malignant neoplasm or past treatment for malignant neoplasm 1 year from screening visit.
- Use of oral CII within the past 1 year. (Since oral tolerance is short-lived, we will permit patients in the study who have been off oral CII for > 1 year)
- Diabetes requiring insulin or on oral medications must be well managed at baseline. Adjustment of insulin or on oral medications will be allowed during the study.
- Serum creatinine 2.0 mcg/dL.
- An 1(II) IFN value <100% of the PBS IFN value within 1 month or less prior to the baseline and less than 25% reduction in APL A12 + 1(II) IFN from 1(II) IFN concentration.
- CDAI > 30 at the baseline visit.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Arm 1
The study will have 3 treatment arms each with 10-12 patients who have demonstrated T cell immunity to CII and have an in vitro response to APL A12 at the screening visit. Patients will be randomized to one of the 2 treatment arms (30 micrograms APL A12 or placebo). Each of the 2 treatments will be given for 16 weeks. Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate. Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate. |
Intervention: Drug treatment will be stopped or interrupted if indicated.
Medical care will be provided at no cost to the patient.
Drug treatment will be stopped or interrupted if indicated.
Medical care will be provided at no cost to the patient.
|
Eksperimentel: Arm 2
The next group will receive a higher dose (50 micrograms) and/or placebo (Block 2). Intervention: Drug treatment will be stopped or interrupted if indicated and medical care will be given as appropriate. |
Intervention: Drug treatment will be stopped or interrupted if indicated.
Medical care will be provided at no cost to the patient.
Drug treatment will be stopped or interrupted if indicated.
Medical care will be provided at no cost to the patient.
|
Eksperimentel: Arm 3
Block 3 (Arm 3) will include placebo and both doses of APL/A12 to ensure 10-12 patients are enrolled in each arm ( total of approximately 32 subjects) so we will have 24 subjects who complete the 16 weeks of study treatment. Arms 2 and 3 will run simultaneously. Intervention: Drug treatment will be stopped or interrupted if indicated. |
Intervention: Drug treatment will be stopped or interrupted if indicated.
Medical care will be provided at no cost to the patient.
Drug treatment will be stopped or interrupted if indicated.
Medical care will be provided at no cost to the patient.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number and Percent of Participants With Reduction of Immunity to Collagen Type-II After APLA-12 Treatment.
Tidsramme: 16 weeks
|
The primary outcome variable is the presence of a > 25% reduction in net IFN concentration in supernatants of 1(II)-stimulated PBMC cultures from baseline after 16 weeks of treatment.
|
16 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Flow Cytometry
Tidsramme: baseline and 8 or 16 weeks
|
Change in Percentage of CD4+CD25+FoxP3 T regulatory cells, CD4+IL-10+ cells, CD4+ IL-4+ cells, CD4+IL17+ cells.
Some patients had only had enough blood collected at 8 weeks or 16 weeks or dropped out after 8 weeks, and we used/combined what was available.
|
baseline and 8 or 16 weeks
|
Clinical Disease Activity Index (CDAI) at 0 and 16 Weeks Follow up
Tidsramme: 0 and16 weeks
|
Interpretation of Clinical Disease Activity Index (CDAI) scores < 2.8 indicate remission; >2.8 and <= 10 indicates low disease activity; >10 and <= 22 indicates moderate disease activity; >22 indicates high disease activity.
|
0 and16 weeks
|
Change in Cytokine Profile From Baseline and 16 Weeks
Tidsramme: 0 and 16 weeks
|
Cytokines assessed are IL-10, IL-13, IL-5, IL-1B, IL-9, IL-17A, IL-6, IL-21, TGF-B, TNFa,and MIP3A.
|
0 and 16 weeks
|
Change in IgG and IgA Immunoglobulin From Baseline to 8 or 16 Weeks
Tidsramme: baseline and 8 or 16 wks
|
The change was computed between baseline and 8 or 16 weeks, whichever was available.
|
baseline and 8 or 16 wks
|
Neutrophils Counts at 0 and 16 Weeks
Tidsramme: Baseline and 16 weeks
|
Laboratory Results of A12 vs Placebo:Complete blood count Neutrophil count to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
Baseline and 16 weeks
|
A12 Treated vs Placebo of Monocytes.
Tidsramme: Baseline and 16 wks
|
Laboratory Results of A12 treated vs Placebo of Monocytes to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
Baseline and 16 wks
|
Eosinophils
Tidsramme: Baseline and 16 weeks
|
Laboratory Results of A12 treated vs Placebo of Eosinophils to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
Baseline and 16 weeks
|
Laboratory Results of A12 vs Placebo: Lymphocytes
Tidsramme: 0-16 weeks
|
Measure to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Laboratory Results of A12 vs Placebo: Basophils
Tidsramme: Baseline and 16 weeks
|
Measure to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
Baseline and 16 weeks
|
Hematocrit
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Laboratory Results of A12 vs Placebo-Total Immunoglobulin (Immature Granulocytes)
Tidsramme: Baseline and 16 weeks
|
Measure to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
Baseline and 16 weeks
|
Red Blood Cell Distribution Width (RDW)
Tidsramme: 0 and 16 weeks
|
Laboratory Results of A12 vs Placebo RDW is a measure of the range of variation of red blood cell volume reported as part of a standard blood count to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0 and 16 weeks
|
Hemaglobin
Tidsramme: Baseline and 16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
Baseline and 16 weeks
|
Red Blood Cells
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
White Blood Count
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Platelets
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
AST, ALT and Alkaline Phosphatase
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Ca, BUN, Glucose,Creatinine, Total Bilirubin
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo-CMP to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Sodium, Potassium and Chloride
Tidsramme: 0-16 weeks
|
Laboratory results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Total Protein, Albumin
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
C-reactive Protein
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Rheumatoid Factor
Tidsramme: 0-16 weeks
|
Laboratory Results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Sedimentation Rate
Tidsramme: 0-16 weeks
|
Laboratory results of A12 vs Placebo to determine whether APL has any effect on routine blood counts, chemistries, electrolytes, immunoglobulin to measure potential toxicities
|
0-16 weeks
|
Laboratory Results of A12 vs Placebo Anti-CCP Antibody
Tidsramme: 0-16 weeks
|
0-16 weeks
|
|
Patient Global Assessment (PGA) and Physician Global Assessment
Tidsramme: 0-16 weeks
|
Patient and Physician (PI) Assessments both range from 0-10 with 10 being the most disease activity
|
0-16 weeks
|
Modified Health Assessment Questionnaire (MHAQ)
Tidsramme: 0-16 weeks
|
Modified Health Assessment Questionnaire (MHAQ) 0-8 with 8 being the most activity
|
0-16 weeks
|
Duration of Morning Stiffness in Joints
Tidsramme: 0-16 weeks
|
Duration of morning stiffness in the joints, in minutes.
|
0-16 weeks
|
CDAI
Tidsramme: 0-16 weeks
|
Clinical Disease Activity Index (CDAI) 0-76 mm.
Interpretation of CDAI scores < 2.8 indicate remission; >2.8 and <= 10 indicates low disease activity; >10 and <= 22 indicates moderate disease activity; >22 indicates high disease activity.
|
0-16 weeks
|
Vital Signs-Temperature
Tidsramme: 0-16 weeks
|
0-16 weeks
|
|
Vital Sign - Pulse
Tidsramme: 0-16 weeks
|
heartbeats per minute
|
0-16 weeks
|
Weight
Tidsramme: 0-16 weeks
|
Weight in kg
|
0-16 weeks
|
Vitals - Blood Pressure
Tidsramme: 0 weeks and 16 weeks
|
measurement of blood pressure (mmHg)
|
0 weeks and 16 weeks
|
Vitals - Respirations
Tidsramme: 0 weeks and 16 weeks
|
Respirations represents breaths per minute
|
0 weeks and 16 weeks
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Arnold E Postlethwaite, MD, Memphis VA Medical Center, Memphis, TN
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IMMA-007-08S
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Rheumatoid arthritis
-
Janssen Research & Development, LLCTrukket tilbageAktiv reumatoid arthritis; Rheumatoid arthritis
-
Healthcare Homoeo Charitable SocietyUkendtRheumatoid arthritis.Indien
-
Federal University of São PauloAfsluttetRheumatoid arthritis.Brasilien
-
Hamad Medical CorporationUkendtRHEUMATOID ARTHRITISQatar
-
Richard Burt, MDAfsluttet
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloUkendt- Rheumatoid arthritisBrasilien
-
Biomet Orthopedics, LLCNew Lexington ClinicAfsluttetSlidgigt | Rheumatoid arthritis | Knæ arthritis | Degenerativ arthritisForenede Stater
-
Biomet Orthopedics, LLCNew Lexington ClinicAfsluttetSlidgigt | Rheumatoid arthritis | Knæ arthritis | Degenerativ arthritisForenede Stater
-
University of SalfordAfsluttetRheumatoid arthritis | Håndslidgigt | Inflammatorisk arthritisDet Forenede Kongerige
-
Link America, Inc.AfsluttetSlidgigt | Rheumatoid arthritis | Post-traumatisk arthritisForenede Stater